The company was founded in 2007 and is one of the earliest companies in China specializing in the development of clinical immunological diagnostic products. Kemei Biotech focuses on the R&D, production, sales and service of in vitroDiagnostics (IVD) products. In September 2019, Beijing Kemei Biotechnology Co., Ltd. completely changed and established Kemei Diagnostic Technology Co., Ltd. The company is a high-tech enterprise mainly engaged in R&D, production and sales of clinical immunochemiluminescence diagnostic reagents and instruments. The company's products are LiCA series diagnostic reagents based on photo-stimulated chemiluminescence and CC series diagnostic reagents and instruments based on enzymatic chemiluminescence. They are mainly used to detect infectious disease (such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.), tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers and inflammation. Corporate honors: It has successively been awarded honorary titles such as National High-tech Enterprise, National Intellectual Property Advantage Enterprise, Zhongguancun High-tech Enterprise, Beijing Specialized and New “Little Giant” Enterprise, Beijing Intellectual Property Demonstration Unit, Beijing Municipal Enterprise Technology Center and National Specialized and New “Little Giant” Enterprise, and Beijing New Technology and New Technology Products (Services).
No Data